A recent antitrust verdict has prompted Takeda to revise its 2025 financials, putting the drugmaker at a 152 billion Japanese yen ($949.37 million) loss for the fiscal year. | The company adjusted its full-year 2025 earnings to account for a legal provision of 402.5 billion JPY ($2.5 billion).

A recent antitrust verdict has prompted Takeda to revise its 2025 financials, putting the drugmaker at a 152 billion Japanese yen ($949.37 million) loss for the fiscal year. |…

Takeda has updated its financial results to reflect costs it could incur after losing an antitrust lawsuit concerning its laxative drug Amitiza.